Tab Application Banner
  • Users Online: 1139
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
BRIEF REPORT
Year : 2021  |  Volume : 16  |  Issue : 2  |  Page : 194-199

Knowledge on hydroxychloroquine prescription and attitude toward its use in COVID-19 – A survey-based study among doctors


1 Department of Dermatology, IQRAA International Hospital and Research Centre, Kerala, India
2 Department of Psychiatry, IQRAA International Hospital and Research Centre, Kerala, India
3 Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
4 Department of Rheumatology, IQRAA International Hospital and Research Centre, Kerala, India
5 Department of Health and Family Welfare, Kerala, India

Correspondence Address:
Dr. T Muhammed Razmi
IQRAA International Hospital and Research Centre, IQRAA International Hospital and Research Centre, IQRAA Aesthetics, Address Mall, Calicut, - 673 001, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/injr.injr_184_20

Rights and Permissions

Background: The use of hydroxychloroquine (HCQ) in COVID-19 had garnered enormous media attention. There were conflicting reports as well as unscientific opinion pieces in the scientific literature also. This study was planned to assess the knowledge, attitude, and practice of health-care professionals regarding HCQ. Methods: An online survey was created with 8 knowledge-based questions (n = 2 fact-based [each scoring 1], n = 6 guideline-based [each scoring 2]), and 6 attitude-based questions, and distribution among a target population of doctors was done using Google™ forms. Results: Of 115 respondents, the majority considered HCQ a safe drug (86.1%) and were in favor of its usage in COVID-19 trials (81.7%) or health-care/contact prophylaxis (60.9%) but against its use as a mass prophylactic agent (80.9%). Contrary to the published guidelines/recommendations, 80% and 55.7% of respondents opined for routine cardiac and glucose-6-phosphate dehydrogenase evaluations before prescribing HCQ. Those who were dealing with COVID-19 patients directly (n = 41) had significantly lower knowledge score compared to the others (6.37 vs. 7.72, P = 0.007). They had significantly lesser awareness for the baseline tests recommended (97.6% vs. 77.0%, P = 0.003). A significantly higher number of these physicians opposed the use of HCQ in clinical trials (26.82% vs. 8.1%, P = 0.027) and health-care/contact prophylaxis (41.5% vs. 16.2%, P = 0.008). Conclusion: Sparse and speedily gathered information on HCQ can influence the practicing doctors, especially those involved directly in COVID-19 patient care, but less familiar with the prescription of this time-tested drug. Possibly, this has a bearing on the counseling of the patients requiring HCQ for non-COVID-19 indications and formulation of new guidelines.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1912    
    Printed41    
    Emailed0    
    PDF Downloaded49    
    Comments [Add]    

Recommend this journal